The truth behind the rumours on Facia
January, 22, 2021
Alaris Lanka Pvt Ltd conducted a press conference on the 20
th Jan 2021 explaining to media regarding the false rumours been circulated about their brand “Facia Premium” Mr. Tharanga Lanka Weerawardana, Chairman and the Managing Director of Alaris Group of Companies stated that a false letter baring the letterhead of the National Medicine Regulatory Authority and false signature of Dr. Kamal Jayasinghe who is the CEO of the National Medicines Regulatory Authority stating that the product Facia Premium has been banned has been circulated in some print & social media. In response to this, the CEO of NMRA has denied the issuance of such letter and instructed the Director of The Fraud Investigation Bureau to conduct an investigation on priority basis” Further he stated that this the two newspapers who published this news have immediately corrected the same after contacting the NMRA and Sri Lanka Customs. Further Face book h
By Steve A. Morrell
Chairman, Bank of Ceylon Kanchana Ratwatte, at the bank’s new year celebrations yesterday said the bank’s profits amounted to Rs.16.5 billion at end 2020. He also said foreign remittances were in excess of 2.5 billion dollars.
The number of account holders of the bank was in excess of 1 million, indicating that the bank’s services were of benefit to every part of the country. The rural sector, inclusive of the farming community, was a growing customer base that benefitted from the bank’s services. Additionally, the SME sector, including entrepreneurs also situated in villages, was within the customer base who continued their dealings with BOC.
Ensuring sustainability in pharma industry: Key focus for 2021 says SLCPI
December, 31, 2020
SLCPI to continue advocating towards a sustainable pricing mechanism
SLCPI calls for ethical practices in the pharmaceutical industry
Digitisation and emerging technologies to impact pharmaceuticals
The Sri Lanka Chamber of the Pharmaceutical Industry (SLCPI) reiterated their commitment towards ensuring the availability of efficacious, safe and good quality medicines to the general public, in the incoming year. When the COVID-19 pandemic forced the Country into lockdown earlier this year, many industries, including Pharmaceuticals, found themselves facing multiple challenges, which inevitably turned into valuable lessons for the year ahead.
Member companies of SLCPI were forced to act quickly to ensure the uninterrupted supply of medicine. They witnessed their business models change in real-time and at an unprecedented pace, which prompted the collaboration of various stakeholders to en
Don’t hesitate to get vaccinated Vaccine hesitancy might deny the herd immunity we are looking for to contain the pandemic. Reuters
IT is without doubt that Covid-19 has dominated our life in 2020. Countries have been struggling to strike a balance between life and livelihood. Relaxing the lockdowns and movement control order to boost the economy would be followed by waves of sudden surges in Covid-19 cases.
But now there is light at the end of the tunnel with the encouraging development of Covid-19 vaccines. This unprecedented pandemic was matched by an unparalleled search for a Covid-19 vaccine.
Vaccines typically require years of research and testing before reaching the clinic, but in 2020, scientists embarked on a race to produce safe and effective coronavirus vaccines in record time.
Bhd are companies leading the charge in the race to supply the Covid-19 vaccine to 32.7 million Malaysians.
Both have fill and finish facilities that have been approved by the National Pharmaceutical Regulatory Authority (NPRA) and are tipped to handle the supply of vaccines that the government purchases.
The priority list for the government is the frontliners and the elderly who are most at risk. That leaves quite a number of people who would want to be inoculated and likely to seek the vaccine from the private healthcare system.
Seizing the opportunity, there are also a host of companies wanting to bring in vaccines to cater to the private sector. From property developers to engineering companies, most are looking at registering the vaccine with the NPRA and distributing it to the private sector.